Menu
Search
|

Menu

Close
X

United Therapeutics Corp UTHR.OQ (NASDAQ Stock Exchange Global Select Market)

125.03 USD
+0.94 (+0.76%)
As of Jul 20
chart
Previous Close 124.09
Open 123.46
Volume 143,528
3m Avg Volume 153,724
Today’s High 126.64
Today’s Low 122.51
52 Week High 152.55
52 Week Low 100.64
Shares Outstanding (mil) 43.54
Market Capitalization (mil) 5,403.38
Forward P/E 9.90
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.17 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY18
389
FY17
1,725
FY16
1,599
FY15
1,466
EPS (USD)
FY18
5.569
FY17
10.955
FY16
15.167
FY15
12.903
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
9.90
33.34
Price to Sales (TTM)
vs sector
3.10
8.11
Price to Book (MRQ)
vs sector
2.27
4.23
Price to Cash Flow (TTM)
vs sector
9.22
22.22
Total Debt to Equity (MRQ)
vs sector
10.47
17.18
LT Debt to Equity (MRQ)
vs sector
10.47
13.08
Return on Investment (TTM)
vs sector
22.95
13.18
Return on Equity (TTM)
vs sector
24.85
15.09

EXECUTIVE LEADERSHIP

Martine Rothblatt
Chairman of the Board, Chief Executive Officer, Since 2016
Salary: $1,163,710.00
Bonus: --
Michael Benkowitz
President, Chief Operating Officer, Since 2016
Salary: $733,333.00
Bonus: --
Christopher Patusky
Lead Independent Vice Chairman of the Board, Since 2007
Salary: --
Bonus: --
James Edgemond
Chief Financial Officer, Treasurer, Since 2015
Salary: $620,833.00
Bonus: --
Paul Mahon
Executive Vice President, General Counsel, Corporate Secretary, Since 2003
Salary: $815,950.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1040 SPRING ST
SILVER SPRING   MD   20910

Phone: +1301.6089292

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

SPONSORED STORIES